BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29391313)

  • 1. Post-transplant malignancies in pediatric liver transplant recipients: Experience of two centers in Turkey.
    Karakoyun M; Önen Ş; Baran M; Çakır M; Ömür Ecevit Ç; Kılıç M; Kantar M; Aksoylar S; Özgenç F; Aydoğdu S
    Turk J Gastroenterol; 2018 Jan; 29(1):89-93. PubMed ID: 29391313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplantation lymphoproliferative disease in pediatric liver recipients in Taiwan.
    Hsu CT; Chang MH; Ho MC; Chang HH; Lu MY; Jou ST; Ni YH; Chen HL; Hsu HY; Wu JF
    J Formos Med Assoc; 2019 Nov; 118(11):1537-1545. PubMed ID: 30630698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
    Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease.
    Rohr JC; Wagner HJ; Lauten M; Wacker HH; Jüttner E; Hanke C; Pohl M; Niemeyer CM
    Pediatr Transplant; 2008 Jun; 12(4):426-31. PubMed ID: 18466428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
    Quintero Bernabeu J; Juamperez J; Mercadal-Hally M; Larrarte King M; Gallego Melcon S; Gros Subias L; Sábado Álvarez C; Soler-Palacin P; Melendo Pérez S; Esperalba J; Navarro Jiménez A; Garrido Pontnou M; Camacho Soriano J; Hidalgo Llompart E; Bilbao Aguirre I; Charco Torra R
    Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Post-transplant lymphoproliferative disease in liver transplant recipients--Merkur University Hospital single center experience].
    Filipec-Kanizaj T; Budimir J; Colić-Cvrlje V; Kardum-Skelin I; Sustercić D; Naumovski-Mihalić S; Mrzljak A; Kolonić SO; Sobocan N; Bradić T; Dolić ZM; Kocman B; Katicić M; Zidovec-Lepej S; Vince A
    Acta Med Croatica; 2011 Sep; 65 Suppl 1():37-43. PubMed ID: 23126028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy.
    Barış Z; Özçay F; Yılmaz Özbek Ö; Haberal N; Sarıalioğlu F; Haberal M
    Turk J Gastroenterol; 2018 May; 29(3):354-360. PubMed ID: 29755021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
    Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo malignancies after liver transplantation: a single-center experience.
    Hegab B; Khalaf H; Allam N; Azzam A; Al Khail FA; Al-hamoudi W; Kamel Y; Al Bahili H; Al Sofayan M; Al-Sebayel M
    Ann Saudi Med; 2012; 32(4):355-8. PubMed ID: 22705604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients.
    Lee TC; Savoldo B; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Barshes NR; Scott JD; Bristow LJ; O'Mahony CA; Goss JA
    Am J Transplant; 2005 Sep; 5(9):2222-8. PubMed ID: 16095501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
    J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients.
    Smets F; Bodeus M; Goubau P; Reding R; Otte JB; Buts JP; Sokal EM
    J Hepatol; 2000 Jan; 32(1):100-4. PubMed ID: 10673073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
    Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
    Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
    Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort.
    Huang JG; Tan MYQ; Quak SH; Aw MM
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29071779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
    J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transplant lymphoproliferative disorders in a cohort of adult patients with a liver transplant from a reference hospital in Bogotá, Colombia.
    Jurado LF; Gómez-Aldana A; Tapias M; Cáceres D; Vera A; López-Panqueva RDP; Andrade RE
    Biomedica; 2020 Sep; 40(3):498-506. PubMed ID: 33030828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.